GENOSKIN’s Post

Exciting Announcement! The International Conference on Vaccine and Immunology is coming to Paris, France, from December 09-11, 2024. Join us as we explore empowering tomorrow's vaccine and immune innovations with a focus on collaboration and hope. This conference is a must-attend for professionals in the vaccine and immunology field. Network with global experts, gain insights into the latest advancements, and contribute to shaping the future of vaccine and immunology. For registration and more information, visit our website: https://lnkd.in/gEG2R8rE Do not miss out on this opportunity to be part of transformative discussions and connect with industry leaders! #vaccine #immunology #Vaccineconference #immunologyconference #Conference2024 #research #development #MedicalConference #HealthcareConference #Sciconx #SciconxConference #ParisConference #CMEConference #CPDConference

Multi-omics is an exciting field and I am happy to have worked with the CMI-PB consortium to build machine learning models for this publication. This paper is just one of many to come, showing how multiomics data and methods can improve vaccinology. https://t.co/pSuYj4CZyb #CompBio #VaccineResearch #Bioinformatics #DataScience #Immunology

***Cancer Vaccines: the Silver Lining of the COVID-19 Pandemic***🩺💉 Amidst the challenges of the COVID-19 pandemic, mRNA technology has surged to the forefront of medical innovation, offering new hope for personalized cancer vaccines. As we embrace these advancements, let's heed the wisdom of the #Greek proverb 'ουδέν κακόν αμιγές καλού'—nothing bad is unmixed with good. 🌟 🧬 While vaccines traditionally prevent infectious diseases by priming the immune system, therapeutic cancer vaccines target proteins produced by cancer cells, sparking a potent immune response against existing tumors. ✨ Though promising results have emerged from various methods, significant hurdles remain:   - Cumbersome trials   - Immune system monitoring   - Scalability    ✨ Let's focus our efforts on overcoming these obstacles—after all, we don't need another pandemic to accelerate progress in cancer therapeutics! #CancerResearch #mRNA #MedicalInnovation #COVID19 #PersonalizedMedicine #CancerVaccines #HopefulFuture   ✍ https://lnkd.in/eij8DWqW

“By identifying the individual factors that affect mRNA circulation, future vaccines may be tailored to personal characteristics, improving efficacy on a case-by-case basis,”   Dr Yi (David) Ju from RMIT University on his team’s new research on how mRNA vaccines circulate and break down in the human bloodstream   The project is a collaboration between research teams at RMIT and The Peter Doherty Institute for Infection and Immunity   With results published in ACS Nano, this study provided key insights that could lead to the development of safer and more effective mRNA vaccines   https://lnkd.in/gUyu8BRz #research #collaboration #mRNAvaccines #mRNA

'Using integrated single cell strategies, we demonstrate that acute PD-1 blockade induces extensive and selective local anti-inflammatory IgG1 plasma cell (PC) differentiation. Expansion of pre-existing IgG1 germinal center (GC) B cell and enhanced GC programming without memory B cell involvement reveals an isotype-specific GC checkpoint that blocks steady-state IgG1 antibody maturation' #Preprint #Immunology #Immunotherapy https://lnkd.in/d2743tU3

We're kicking off Women's History Month by shining a light on the incredible Dr. Kizzmekia S Sorbett-Helaire and her contributions to developing the COVID-19 vaccine! Dr. Corbett uses her viral immunology expertise to propel novel vaccine development for pandemic preparedness, including mRNA-1273, a leading vaccine against SARS-CoV-2. The vaccine concept incorporated in mRNA-1273 was designed by Dr. Corbett's NIH team from viral sequence and rapidly deployed to industry partner, Moderna, Inc., for Phase 1 clinical trial, which unprecedently began only 66 days from viral sequence release. mRNA-1273 was shown to be 94.1% effective in Phase 3 trial and is authorized for use in multiple countries. Learn more about her: https://bit.ly/4c4NE2M #WomensHistoryMonth #CelebrateWomen #InnovativeWomen #Leadership #Vaccines #Immunization #HealthCare #IMWI

Finally online!!! Check it out!!! https://lnkd.in/erdbVAbX Disease-modifying therapies (DMT) administered to patients with multiple sclerosis (MS) can influence immune responses to SARS-CoV-2 and vaccine efficacy. However, data on the detailed phenotypic, functional and metabolic characteristics of antigen (Ag)-specific cells following the third dose of mRNA vaccine remain scarce. Here, using flow cytometry and 45-parameter mass cytometry, we broadly investigate the phenotype, function and the single-cell metabolic profile of SARS-CoV-2-specific T and B cells up to 8 months after the third dose of mRNA vaccine in a cohort of 94 patients with MS treated with different DMT, including cladribine, dimethyl fumarate, fingolimod, interferon, natalizumab, teriflunomide, rituximab or ocrelizumab. Almost all patients display functional immune response to SARS-CoV-2. Different metabolic profiles characterize antigen-specific-T and -B cell response in fingolimod- and natalizumab-treated patients, whose immune response differs from all the other MS treatments. #scMEP #masscytometry #MS #SARS-CoV-2 #vaccination #prediction

Vaccine-based protection from COVID-19 wanes over time, especially in older adults. To address this problem, NIAID-supported researchers added mRNA encoding immune protein IL-12 to a COVID-19 mRNA vaccine, raising immune responses in aged mice to levels akin to those seen in young adult mice. IL-12 is important for responding well to vaccination, but natural production of this protein declines as people and mice age. For safety, researchers designed the adjuvant so only the muscle where it is injected makes the protein. These findings could mark a step toward better COVID-19 mRNA vaccines for older adults. Learn more: https://lnkd.in/eTThbX9Q #NIH #NIAID #COVID19 #mRNA #immunology #science #research #ScienceTranslationalMedicine Boston Children's Hospital Brigham and Women's Hospital Combined Therapeutics

Formulating a dry-powder vaccine based on liposomes: Eliane N. Miyaji at Instituto Butantan and collaborators produced liposomes that encapsulated PspA proteins using microfluidics. These were then turned into nanocomposite microparticles carriers using spray-drying, resulting in a stable substrate that maintained protein activity. Mice were immunized with LP/NCMPs containing PspA1 and/or PspA4Pro to target the lungs, with results suggesting the possibility of providing enduring protection https://lnkd.in/eHWNQa_Z also authored by Tasson da Costa Rodrigues, Douglas Borges de Figueiredo, Viviane Goncalves, Kan Kaneko and Imran Saleem #liposomes #vaccines #pneumonia #immunology #Vesiculab